GLP1 Agonists Reduce Major Adverse Liver Outcomes in Chronic Liver Disease
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 29, 2024 -- For patients with chronic liver disease and type 2 diabetes, glucagon-like peptide-1 receptor (GLP1) agonists may result in a lower risk for major adverse liver outcomes (MALO), according to a study published online Jan. 22 in Gut.
Axel Wester, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues used observational data from Swedish health care registers from 2010 to 2020 to emulate a target trial of GLP1 agonists in eligible patients with chronic liver disease and type 2 diabetes. An inverse-probability weighted marginal structural model was used to compare parametric estimates of 10-year MALO risk in initiators of GLP1 agonists and noninitiators.
The researchers found that the 10-year risk for MALO was 13.3 and 14.6 percent in GLP1 agonist initiators and noninitiators, respectively, in an intention-to-treat analysis (risk ratio [RR], 0.91; 95 percent confidence interval [CI], 0.50 to 1.32). The corresponding per-protocol risk estimates at 10 years were 7.4 and 14.4 percent (RR, 0.51; 95 percent CI, 0.14 to 0.88). At six and eight years, the corresponding per-protocol risk estimates were 5.4 versus 9.0 percent (RR, 0.60; 95 percent CI, 0.29 to 0.90) and 7.2 versus 11.7 percent (RR, 0.61; 95 percent CI, 0.21 to 1.01).
"The risk of MALO in patients with chronic liver diseases and type 2 diabetes was lower if they initiated a GLP1 agonist and adhered to this treatment over time," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 -- For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists...
Diabetes Tied to Higher Prevalence of Overactive Bladder
TUESDAY, June 4, 2024 -- Markers of diabetes are positively associated with overactive bladder (OAB), according to a study published online April 28 in Frontiers in...
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.